Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?

The cost differential between these two drugs is no longer defensible.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical journal of Australia 2011-06, Vol.194 (11), p.567-568
Hauptverfasser:	Harvey, Ken J, Day, Richard O, Campbell, William G, Lipworth, Wendy
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - economics Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - economics Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Australia Bevacizumab Eye diseases Health Policy Health services administration Humans Macular Degeneration - drug therapy National Health Programs - economics Off-Label Use Pharmaceutical preparations Randomized Controlled Trials as Topic Ranibizumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The cost differential between these two drugs is no longer defensible.
ISSN:	0025-729X 1326-5377
DOI:	10.5694/j.1326-5377.2011.tb03105.x